263 related items for PubMed ID: 17593865
1. Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma.
Tatsis G, Kotsifas K, Filaditaki V, Makrantoni G, Boulia S.
J Int Med Res; 2007; 35(3):361-73. PubMed ID: 17593865
[Abstract] [Full Text] [Related]
2. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM.
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[Abstract] [Full Text] [Related]
3. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
Aubier M, Wettenger R, Gans SJ.
Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
[Abstract] [Full Text] [Related]
4. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ, Currie GP, Lipworth BJ.
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[Abstract] [Full Text] [Related]
5. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[Abstract] [Full Text] [Related]
6. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control.
Worth H, Muir JF, Pieters WR.
Respiration; 2001 Jan; 68(5):517-26. PubMed ID: 11694816
[Abstract] [Full Text] [Related]
7. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
Farmer IS, Middle M, Savic J, Perri VL, Herdman MJ.
Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
[Abstract] [Full Text] [Related]
8. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.
Pauwels RA, Yernault JC, Demedts MG, Geusens P.
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):827-32. PubMed ID: 9517598
[Abstract] [Full Text] [Related]
9. Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone.
Horiguchi T, Hayashi N, Ohira D, Torigoe H, Ito T, Hirose M, Sasaki Y, Shiga M, Miyazaki J, Kondo R, Tachikawa S.
J Asthma; 2006 Sep; 43(7):509-12. PubMed ID: 16939990
[Abstract] [Full Text] [Related]
10. [A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate].
Ohbayashi H, Adachi M, Ichinose M, Ohta K, Kokubu F, Sano Y, Tamura G, Tohda Y, Hirata K, Yasuba H.
Arerugi; 2007 Jun; 56(6):577-86. PubMed ID: 17615501
[Abstract] [Full Text] [Related]
11. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics.
Anderson PB, Langley SJ, Mooney P, Jones J, Addlestone R, Rossetti A, Cantini L.
J Investig Allergol Clin Immunol; 2002 Jun; 12(2):107-13. PubMed ID: 12371526
[Abstract] [Full Text] [Related]
12. Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.
Juniper EF, Buist AS.
Chest; 1999 Nov; 116(5):1297-303. PubMed ID: 10559091
[Abstract] [Full Text] [Related]
13. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.
Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ, Pediatric Study Group.
Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586
[Abstract] [Full Text] [Related]
14. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months.
Boulet LP, Cartier A, Ernst P, Larivée P, Laviolette M.
Can Respir J; 2004 Mar; 11(2):123-30. PubMed ID: 15045043
[Abstract] [Full Text] [Related]
15. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.
Dahl R, Ringdal N, Ward SM, Stampone P, Donnell D.
Br J Clin Pract; 1997 Mar; 51(1):11-5. PubMed ID: 9158265
[Abstract] [Full Text] [Related]
16. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study.
Wolthers OD, Walters EG.
Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529
[Abstract] [Full Text] [Related]
17. Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma.
Gillissen A, Richter A, Oster H, Criée CP.
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):233-41. PubMed ID: 18204133
[Abstract] [Full Text] [Related]
18. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A, Williams A, Batty L, Masterson C, Rossetti A, Cantini L.
J Aerosol Med; 2002 Nov; 15(4):407-14. PubMed ID: 12581507
[Abstract] [Full Text] [Related]
19. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial.
Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EE, Arora S, Pedersen S, Pediatric Study Group.
J Allergy Clin Immunol; 2002 Jul; 110(1):45-50. PubMed ID: 12110818
[Abstract] [Full Text] [Related]
20. [The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation].
Ohbayashi H.
Arerugi; 2005 Jan; 54(1):24-35. PubMed ID: 15841673
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
